Jump to navigation
The latest clinical and political news for Australian Rheumatologists
Snapshot from real-world data on treatment duration in rheumatoid arthritis.
It's not just about the ageing population, specialists say.
ACCC says legal case resembles $6 milllion action on Nurofen specific branding.
Most US advice is based on opinion or case reports.
Study shows cells in inflamed joints have low sensitivity to 1,25(OH)D3.
Multi-disciplinary care largely a pipe dream, study shows.
Methotrexate appears to at least delay RA onset.
A long-term patient needs hospital care. But was her management evidence-based?
Evidence is being ignored despite concern over harms and cost, researchers say.
Febuxostat linked to increased risk of cardiac and all-cause mortality.
Stepwise febuxostat | Assessing patient fears | Resistance exercise in RA
Study evaluates risks lor low bone mineral density.
But there’s a question mark over skin cancers.
A physician-driven initiative.
Five times as many women as men are affected.
The latest on lupus.
The risk is similar to that conferred by having diabetes, research shows.
Australian research shows mannose binding lectin deficiency raises risk.
Among other benefits, patients are more satisfied.
Fears about teratogenicity appear unfounded.
Australian Doctor Group (ADG) is Australia’s premier business to business publisher, delivering the country’s most recognised industry magazines and websites.
Ensure you never miss a big story by signing up for our daily e-newsletter.